Free Trial

Quanterix (QTRX) Competitors

$14.49
+0.41 (+2.91%)
(As of 07/12/2024 ET)

QTRX vs. FLDM, BNGO, TXG, CTKB, LAB, EYPT, PACB, NAUT, HBIO, and SEER

Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include Fluidigm (FLDM), Bionano Genomics (BNGO), 10x Genomics (TXG), Cytek Biosciences (CTKB), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Pacific Biosciences of California (PACB), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), and Seer (SEER).

Quanterix vs.

Fluidigm (NASDAQ:FLDM) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.

Quanterix has a consensus target price of $28.60, suggesting a potential upside of 97.38%.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fluidigm
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Quanterix
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Fluidigm received 248 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 65.15% of users gave Fluidigm an outperform vote while only 61.75% of users gave Quanterix an outperform vote.

CompanyUnderperformOutperform
FluidigmOutperform Votes
516
65.15%
Underperform Votes
276
34.85%
QuanterixOutperform Votes
268
61.75%
Underperform Votes
166
38.25%

Quanterix has lower revenue, but higher earnings than Fluidigm. Quanterix is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fluidigm$130.58M0.00-$59.24M-$0.78N/A
Quanterix$122.37M4.53-$32.33M-$0.96-15.09

In the previous week, Quanterix had 7 more articles in the media than Fluidigm. MarketBeat recorded 7 mentions for Quanterix and 0 mentions for Fluidigm. Fluidigm's average media sentiment score of 0.40 beat Quanterix's score of 0.28 indicating that Quanterix is being referred to more favorably in the news media.

Company Overall Sentiment
Fluidigm Neutral
Quanterix Neutral

76.6% of Fluidigm shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 2.9% of Fluidigm shares are held by insiders. Comparatively, 6.9% of Quanterix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Fluidigm has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -45.36%. Fluidigm's return on equity of -10.39% beat Quanterix's return on equity.

Company Net Margins Return on Equity Return on Assets
Fluidigm-45.36% -40.15% -14.86%
Quanterix -28.82%-10.39%-8.57%

Summary

Quanterix beats Fluidigm on 10 of the 15 factors compared between the two stocks.

Get Quanterix News Delivered to You Automatically

Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QTRX vs. The Competition

MetricQuanterixAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$554.53M$4.92B$5.25B$8.68B
Dividend YieldN/A0.45%2.84%4.09%
P/E Ratio-15.0926.68154.5718.00
Price / Sales4.535.382,129.4686.98
Price / CashN/A38.5634.1232.05
Price / Book1.583.044.934.48
Net Income-$32.33M-$11.37M$110.52M$215.59M
7 Day Performance18.48%5.74%6.11%5.39%
1 Month Performance-18.46%-4.33%3.93%3.29%
1 Year Performance-41.34%-35.74%6.07%1.91%

Quanterix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLDM
Fluidigm
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A$283.76M$130.58M-4.76615Analyst Forecast
BNGO
Bionano Genomics
1.1399 of 5 stars
1.14 / 5 stars
$0.65
+3.2%
$4.00
+517.7%
-89.9%$43.30M$36.12M-0.11344Short Interest ↑
TXG
10x Genomics
4.3973 of 5 stars
4.40 / 5 stars
$15.71
-13.9%
$41.92
+166.9%
-70.6%$1.87B$618.73M-7.041,259Analyst Forecast
News Coverage
Gap Up
High Trading Volume
CTKB
Cytek Biosciences
2.2851 of 5 stars
2.29 / 5 stars
$5.59
-2.6%
$8.63
+54.3%
-34.7%$733.80M$193.01M-62.10676Positive News
Gap Up
LAB
Standard BioTools
3.7724 of 5 stars
3.77 / 5 stars
$1.76
-4.3%
$3.58
+103.6%
-16.5%$651.94M$106.34M-1.74534Short Interest ↓
News Coverage
Positive News
Gap Up
EYPT
EyePoint Pharmaceuticals
2.4868 of 5 stars
2.49 / 5 stars
$8.69
-0.9%
$33.29
+283.0%
+11.7%$452.58M$46.02M-4.77121Short Interest ↑
PACB
Pacific Biosciences of California
2.4185 of 5 stars
2.42 / 5 stars
$1.30
-0.8%
$6.38
+390.4%
-87.8%$354.07M$200.52M-1.14796Gap Up
NAUT
Nautilus Biotechnology
1.1934 of 5 stars
1.19 / 5 stars
$2.27
+0.4%
$5.00
+120.3%
-30.7%$284.34MN/A-4.13167Gap Up
HBIO
Harvard Bioscience
1.0683 of 5 stars
1.07 / 5 stars
$2.88
+3.6%
N/A-42.6%$125.08M$112.25M-14.40391Short Interest ↑
SEER
Seer
2.3475 of 5 stars
2.35 / 5 stars
$1.59
flat
$7.00
+340.3%
-62.5%$102.98M$16.66M-1.22147Short Interest ↓
News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:QTRX) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners